Please select the option that best describes you:
For cisplatin ineligible patients with locally advanced head and neck cancer, would you consider RT + immunotherapy rather than RT + cetuximab?
In light of recent trials showing no difference in outcomes with RT+cetuximab vs RT+IO, does this potentially lead us to use immunotherapy in cisplatin-ineligible patients?
IO is typically easier to administer and manage than cetuximab. Can we extrapolate this from the trials?
Answer from: Radiation Oncologist at Academic Institution
No. While the cited GORTEC trial showed pembrolizumab was no worse than cetuximab, the results from HN004 showed a significant reduction in PFS in the durvalumab arm. This plus emerging data from the lab of @Sana D. Karam (Darragh et al., PMID 36385142) showing that elective nodal radiation sig...
Sign in or Register to read more